Case Report: Neoadjuvant chemoimmunotherapy achieving pathological complete response in two cases of stage III EGFR-mutant NSCLC with high PD-L1 expression - Top-Institutions - MDSpire

Case Report: Neoadjuvant chemoimmunotherapy achieving pathological complete response in two cases of stage III EGFR-mutant NSCLC with high PD-L1 expression

By
Diming Wang
Tangbin Liu
Jian Zhao
Bowen Ding
Yongliang Niu
June 17, 2026
0 min

Frontiers In Oncology

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

#1

The University of Texas MD Anderson Cancer Center

Houston, Texas
Key Differentiators
- Lung Cancer
- Thoracic Oncology
#2

Memorial Sloan Kettering Cancer Center

New York, New York
Key Differentiators
- Thoracic Oncology
- Lung Cancer
#3

Dana-Farber Cancer Institute

Boston, Massachusetts
Key Differentiators
- Medical Oncology
- Lung Cancer
#4

Dana-Farber/Brigham and Women’s Hospital

Boston, Massachusetts
Key Differentiators
- Medical Oncology
- Lung Cancer
#5

Sidney Kimmel Comprehensive Cancer Center

Baltimore, Maryland
Key Differentiators
- Medical Oncology
- Lung Cancer

Original Source(s)

Frontiers In Oncology

Case Report: Neoadjuvant chemoimmunotherapy achieving pathological complete response in two cases of stage III EGFR-mutant NSCLC with high PD-L1 expression

by Diming Wang, Tangbin Liu, Jian Zhao, Bowen Ding, Yongliang Niu
June 17, 2026

Related Content

Frontiers In Oncology

Alectinib shows promise for the treatment of refractory ALK-positive large B-cell lymphoma: a case report

by Atheer Alsulami, Roula Almufti, Saleem Eldadah, Yahya Al-Ghamdi
June 17, 2026

Frontiers In Medicine

Clinical outcomes of tebentafusp in metastatic uveal melanoma: a systematic review and single-arm meta-analysis

by Han Cai, Zhilong Huang, Bing-Long Wang, Ming Wei, Miao Tian, Hongmei Zheng
June 17, 2026

Frontiers In Immunology

Correction: MAPRE2 is associated with macrophage-enriched innate immune dysregulation and malignant phenotypes in hepatocellular carcinoma